✦ LIBER ✦

85P BENEFIT OF MAINTENANCE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ACCORDING TO RESPONSE TO FIRST LINE THERAPY

✍ Scribed by Garde, J.; García, J.; Marin, S.; Berzosa, M.; Sangrador, C.; Hidalgo, J.; Piera, N.; Juan, O.; Llombart, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly docetaxel as first-line therapy f

✍ Hainsworth, J.D; Burris, H.A; Morrissey, L.H; Litchy, S; Greco, F.A 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Gefitinib as first-line, compassionate u

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Maintenance therapy for patients with ad

✍ S. I. Rothschild; O. Gautschi 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 207 KB

P-612 Gefitinib (Iressa, ZD1839) is acti

✍ Argiris, Athanassios; Mittal, Namrata; Masters, Gregory 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Current Approaches to Advanced-Stage Non

✍ Thomas E. Stinchcombe; Carrie B. Lee; Mark A. Socinski 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 134 KB

9005 ORAL Is There a Benefit to Maintena

✍ DesGuetz, G.; Uzzan, B.; Chouahnia, K.; Nicolas, P.; Perol, M.; Morere, J.F. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB